NW PHARMATECH
is a Clinical Stage Biotech Company with a Focus on Psychiatric & Neurological Disorders
About NW PharmaTech
NWPharmaTech’s expert team combines academic research, cutting-edge technology, and clinical development to bring to market new drug formulations to combat mental health conditions.
These therapeutic interventions will support a return to homeostasis, empowering patients to lead longer and healthier lives.
Initial Target Indications – Psychiatric and Neurological Disorders
We are advancing to late-stage clinic development in two primary areas: Clinical High Risk for Psychosis & General Anxiety Disorder.
Our Mission
Mental health is a complex and underserved global pandemic, further exacerbated by COVID-19.
Many of the solutions available to patients today are poor as drugs often come with unwanted side effects or lack of efficacy. Our mission is to introduce improved treatment options and thus to aid a vast number of patients suffering from debilitating mental health conditions, and help them return towards a state of homeostasis, thereby allowing them to live longer and happier lives.
We plan to achieve this through a strategy rooted in rigorous science and a best-in-class team with long standing expertise in the pharmaceutical and life sciences sectors.
THE MENTAL HEALTH PANDEMIC IN NUMBERS
The G7 countries spend $3.9tn per annum on mental health (8.9% of overall health spending)1
Anxiety
Up to 30% of adults affected over their lifetime 2, accounting for a third of all mental health expenditures ($1.3tn per annum in the G7 countries) 3
Psychosis
Around 3% of people will suffer from a psychotic disorder in their lifetime 4, costing the US alone $280bn per annum 5
Global sleep crisis
Over 30% of adults affected 6, costing the G7 countries $675bn per annum (1.5% of GDP) 7
CONTACT US
1: Data from OECD (data.oecd.org) and World Health Organization (who.int/data/gho)
2: “Epidemiology of anxiety disorders in the 21st century”, Dialogues in Clinical Neuroscience, Borwin Bandelow et al., 2015
3: “Economic costs of anxiety disorders”, Anxiety vol. 2,4 (1996), R L DuPont et al., 1996
4: ”Understanding Psychosis”, National Institute of Mental Health, NIH Publication No. 20-MH-8110, 2020
5: “Societal Costs of Schizophrenia & Related Disorders”, Schizophrenia & Psychosis Action Alliance, Publication July 2021
6: “Insomnia Overview: Epidemiology, Pathophysiology, Diagnosis and Monitoring, and Nonpharmacologic Therapy”, AJMC, Julie Dopheide, 2020
7: “Why Sleep Matters—The Economic Costs of Insufficient Sleep”, Rand Health Quarterly, Marco Hafner et al., 2017